Gleason IP

< Back to News

Navigating Patent Litigation Changes: Update on the America Invents Act

January 1, 2017

In Issue 3 of IP Insights, we discussed the Inter Partes Review (IPR) process at the United States Patent and Trademark Office (USPTO) since the Leahy-Smith America Invents Act (AIA) was signed into law. The AIA was approved as part of an effort to improve the quality of the patents issued by the USPTO, to...   Read More

Tags:  Gleason IP

Increased Attention on Pharmaceutical Prices

January 1, 2017

As healthcare costs continue to rise, more and more people have entered the debate over escalating drug prices. One situation that has captured the attention of many involves the drug Daraprim®. Daraprim® (pyrimethamine) is used to treat toxoplasmosis in patients with weak immune systems, such as HIV patients.1 Although Daraprim® has been around for over...   Read More

Tags:  Gleason IP

Gleason IP Helps Clients Win Patent Infringement Case

January 1, 2017

Engagement In a pharmaceutical patent infringement matter, Ivan Hofmann and the team at Gleason IP analyzed various issues and provided expert opinions and testimony concerning objective indicia of nonobviousness related to a patent that allegedly covered a lyophilized formulation of the injectable cancer drug bortezomib (marketed as Velcade®). Specifically, Gleason IP analyzed commercial success as...   Read More

Tags:  Gleason IP